COYA
Coya Therapeutics Inc (COYA)
Healthcare • NASDAQ • $5.32-1.30%
- Symbol
- COYA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $5.32
- Daily Change
- -1.30%
- Market Cap
- $115.41M
- Trailing P/E
- N/A
- Forward P/E
- -2.69
- 52W High
- $7.75
- 52W Low
- $3.71
- Analyst Target
- $15.21
- Dividend Yield
- N/A
- Beta
- 0.62
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; CO…
Company websiteResearch COYA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.